Synthesis and cytotoxicity studies of bifunctional hybrids of nitrogen mustards with potential enzymes inhibitors based on melamine framework

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 27, Issue 5, 2012, Pages 619-627

  Kolesinska, Beata ^a   Barszcz, Konrad ^a   Kaminski, Zbigniew J ^a   Drozdowska, Danuta ^b   Wietrzyk, Joanna ^c   Switalska, Marta ^c  

^a LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Alkylating agent; Apoptosis; Hybrid anticancer drugs; Nitrogen mustard; Proliferation inhibitors; Triazine scaffold

Indexed keywords

2 [4 (2 CHLOROETHYL) PIPERAZIN 1 YL] 4,6 BIS (2,2,2 TRIFLUOROETHOXY) [1,3,5]TRIAZINE; 2 [4 (2 CHLOROETHYL) PIPERAZIN 1 YL] 4,6 DIPHENOXY [1,3,5]TRIAZINE; 2,4 BIS [4 (2 CHLOROETHYL) PIPERAZIN 1 YL] 6 METHOXY [1,3,5]TRIAZINE; 2,4 BIS BENZYLOXY 6 [4 (2 CHLOROETHYL) PIPERAZIN 1 YL] [1,3,5]TRIAZINE; 2,4 BIS METHOXY 6 [4 (2 CHLOROETHYL) PIPERAZIN 1 YL] [1,3,5]TRIAZINE; 2,4,6 TRIS [4 (2 CHLOROETHYL) PIPERAZIN 1 YL] [1,3,5]TRIAZINE; ANTINEOPLASTIC AGENT; CHLORMETHINE; ENZYME INHIBITOR; HYBRID ANTINEOPLASTIC AGENT; MELAMINE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; COLORECTAL CARCINOMA; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITOR COMPLEX; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; LEUKEMIA; LUNG CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY; TUMOR CELL;

CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MCF-7 CELLS; MECHLORETHAMINE; TRIAZINES;

BRASSICACEAE; MAMMALIA;

EID: 84866072432     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.604482     Document Type: Article

References (36)

1. He J, Anderson MH, Shi W, Eckert R. Design and activity of a 'dual-targeted' antimicrobial peptide. Int J Antimicrob Agents 2009;33:532-537.
2. (a) Feyen F, Cachoux F, Gertsch J, Wartmann M, Altmann KH. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc Chem Res 2008;41:21-31
3. b) Hulsman N, Medema JP, Bos C, Jongejan A, Leurs R, Smit MJ, et al. Chemical insights in the concept of hybrid drugs: The antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem 2007;50:2424-2431. (Pubitemid 46799254)
4. for review see (a) Ben Abid F, Gazzah A, Ousbane A, Gutierrez M, Brain E. Les alkylants. Oncologie 2007;9:751-757 (Pubitemid 350246983)
5. Di Francesco AM, Hargreaves RH, Wallace TW, Mayalarp SP, Hazrati A, Hartley JA, et al. The abnormal cytotoxicities of 2,5-diaziridinyl-1,4- benzoquinone-3-phenyl esters. Anticancer Drug Des 2000;15:347-359 (Pubitemid 32441350)
6. Vedejs E, Naidu BN, Klapars A, Warner DL, Li VS, Na Y, Kohn H. Synthetic enantiopure aziridinomitosenes: Preparation, reactivity, and DNA alkylation studies. J Am Chem Soc 2003;125:15796-15806 and references cited therein.
7. Maeda M, Ligo M, Tsuda H, Fujita H, Yonemura Y, Nakagawa K et al. Antimetastatic and antitumor effects of 2,4-diamino-6-(pyridine-4-yl)-1,3,5- triazine (4PyDAT) on the high lung metastatic colon 26 tumor in mice. Anticancer Drug Des 2000;15:217-223.
8. Paquin I, Raeppel S, Leit S, Gaudette F, Zhou N, Moradei O et al. Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett 2008;18:1067-1071. (Pubitemid 351179338)
9. Riou JF, Guittat L, Mailliet P, Laoui A, Renou E, Petitgenet O et al. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc Natl Acad Sci usa 2002;99:2672-2677 (Pubitemid 34240519)
10. Gomez D, Aouali N, Londono-Vallejo A, Lacroix L, Megnin-Chanet F, Lemarteleur T, et al. Resistance to the short term anti-proliferative activity of the g-quadruplex ligand 12459 Is Associated with telomerase overexpression and telomere capping alteration. J Biol Chem 2003;278:50554-50562. (Pubitemid 37548902)
11. Mandal S, Bérubé G, Asselin E, Mohammad I, Richardson VJ, Gupta A et al. A novel series of potent cytotoxic agents targeting G2/M phase of the cell cycle and demonstrating cell killing by apoptosis in human breast cancer cells. Bioorg Med Chem Lett 2007;17:4955-4960. (Pubitemid 47187684)
12. Chandra M, Sahay AN, Pandey DS, Tripathi RP, Saxena JK, Reddy VJM, et al. Potential inhibitors of DNA topoisomerase II. Ruthenium (II) polypyridyl and pyridyl azine complexes; potential DNA cleaving agents. J Organomet Chem 2004;689:2256-2267.
13. Kaminski ZJ, Kolesinska B, Markowicz SW. Synthesis and cytostatic properties of monoterpene derivatives of cyanuric and isocyanuric acids. Acta Pol Pharm 2004;61 Suppl:29-32.
14. Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. j Med Chem 2004;47:2550-2560. (Pubitemid 38580092)
15. Henke BR, Consler TG, Go N, Hale RL, Hohman DR, Jones SA et al. A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta. j Med Chem 2002;45:5492-5505. (Pubitemid 35424967)
16. Prade L, Huber R, Bieseler B. Structures of herbicides in complex with their detoxifying enzyme glutathione S-transferase -explanations for the selectivity of the enzyme in plants. Structure 1998;6:1445-1452. (Pubitemid 28541887)
17. Li R, Sirawaraporn R, Chitnumsub P, Sirawaraporn W, Wooden J, Athappilly F et al. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. j Mol Biol 2000;295:307-323. (Pubitemid 30045362)
18. Lancaster CR, Michel H Refined crystal structures of reaction centres from Rhodopseudomonas viridis in complexes with the herbicide atrazine and two chiral atrazine derivatives also lead to a new model of the bound carotenoid. j Mol Biol 1999;286:883-898. (Pubitemid 29106224)
19. Kim YJ, Sackett DL, Schapira M, Walsh DP, Min J, Pannell LK et al. Identification of 12Cysbeta on tubulin as the binding site of tubulyzine. Bioorg Med Chem 2006;14:1169-117
20. Verheijen JC, Richard DJ, Curran K, Kaplan J, Yu K, Zask A. Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl) triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability. Bioorg Med Chem Lett 2010;20:2648-2653
21. Venkatesan AM, Dehnhardt CM, Santos ED, Chen Z, Dos Santos, O, Ayral-Kaloustian S, et al. Bis(morpholino-1,3,5-triazine) derivatives: Potent adenosine 50-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: Discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem 2010;53:2636-2645.
22. Retailleau P, Colloc'h N, Vivares D, Bonneté F, Castro B, El-Hajji M et al. Complexed and ligand-free high-resolution structures of urate oxidase (Uox) from Aspergillus flavus: A reassignment of the active-site binding mode. Acta Crystallogr d Biol Crystallogr 2004;60:453-462. (Pubitemid 41087573)
23. Kumar R, Gupta L, Pal P, Khan S, Singh N, Katiyar SB et al. Synthesis and cytotoxicity evaluation of (tetrahydro-beta-carboline)-1,3,5-triazine hybrids as anticancer agents. Eur J Med Chem 2010;45:2265-2276.
24. Moreau D, Jacquot C, Tsita P, Chinou I, Tomasoni C, Juge M et al. Original triazine inductor of new specific molecular targets, with antitumor activity against nonsmall cell lung cancer. Int J Cancer 2008;123:2676-2683.
25. Nieto Y. DNA-binding agents. Cancer Chemother Biol Response Modif 2005;22:163-20
26. Kaldor JM, Day NE, Hemminki K. Quantifying the carcinogenicity of antineoplastic drugs. Eur J Cancer Clin Oncol 1988;24:703-711. (Pubitemid 18095576)
27. Kamiński ZJ, Kolesińska B, Kinas R, Jastrzabek K, Kolesińska J, The method of manufacturing of trisubstituted triazine derivatives. Pl Pat. Appl P-360-728.
28. (a) SRB test according to: Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst 1990;82:1107-1112 (Pubitemid 20213250)
29. MTT test according to: Marcinkowska E, Kutner A, Radzikowski C. Cell differentiating and anti-proliferative activity of side-chain modified analogues of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 1998;67:71-78. (Pubitemid 28545120)
30. Petrelli A, Valabrega G. Multitarget drugs: The present and the future of cancer therapy. Expert Opin Pharmacother 2009;10:589-600;
31. (b) Wei D, Jiang X, Zhou L, Chen J, Chen Z, He C, et al. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem 2008;51:7882-7888.
32. Nieto Y. DNA-binding agents. Cancer Chemother. Biol Response Modif 2005;22:163-203.
33. Kolesińska B, Kamiński ZJ. Transformation of Tertiary Amines into alkylating reagents by treatment with 2-chloro-4,6-dimethoxy-1,3,5- triazine. A synthetic application of side-reaction accompanying coupling by means of 4-(4,6-dimethoxy-[1,3,5] triazin-2-yl)-4-methyl-morpholin-4-ium chloride (DMTMM). Pol J Chem 2008;82:2115-2123.
34. Kolesińska B, Kamiński ZJ. The umpolung of substituent effect in nucleophilic aromatic substitution. A new approach to the synthesis of N,N-disubstituted melamines (triazine triskelions) under mild reaction conditions. Tetrahedron 2009;65: 3573-3576.
35. Zon G. Cyclophosphamide analogues. Prog Med Chem 1982;19: 205-246.
36. Preussmann R, Schneider H, Epple F. Identification of alkylating agents. II. Identification of different classes of alkylating agents by a modification of the color reaction with 4-(4-nitrobenzyl)-pyridine (NBP). Arzneimittelforschung 1969;19:1059-1073